Bavarian Nordic
Bavarian Nordic A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach in the field of immunotherapy and vaccine development. Founded in 1994, the company has made significant strides in combating infectious diseases and cancer, with a strong operational presence across Europe and North America. Specialising in the development of live virus vaccines and immunotherapies, Bavarian Nordic's core products include the smallpox vaccine, IMVAMUNE®, and the cancer immunotherapy candidate, BN-Brachyury. These offerings are distinguished by their unique mechanisms and robust safety profiles, positioning the company as a key player in the biopharmaceutical industry. With a commitment to advancing public health, Bavarian Nordic has achieved notable milestones, including partnerships with global health organisations, solidifying its reputation as a trusted innovator in vaccine technology.
DitchCarbon Score
How does Bavarian Nordic's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bavarian Nordic's score of 44 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bavarian Nordic's reported carbon emissions
In 2023, Bavarian Nordic reported total carbon emissions of approximately 43,640,000 kg CO2e for Scope 1 and about 63,182,000 kg CO2e for Scope 2. This marks a significant increase in emissions compared to 2022, where Scope 1 emissions were about 1,765,000 kg CO2e and Scope 2 emissions were approximately 988,000 kg CO2e. The company has not disclosed any Scope 3 emissions data. Bavarian Nordic has committed to achieving Net Zero emissions by 2050, in alignment with the Paris Agreement on Climate Change. In 2024, the company plans to define its carbon footprint reduction pathway, demonstrating its determination to reduce emissions across all scopes. This commitment reflects a proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector. The company has also reported a carbon footprint of approximately 7,800 kg CO2e per employee in 2023, indicating a focus on employee-related emissions as part of its sustainability strategy. Overall, Bavarian Nordic's climate commitments and emissions data highlight its ongoing efforts to address climate change and improve sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 992,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,686,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bavarian Nordic is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
